Many Nivalis Therapeutics, Inc.(NVLS) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Nivalis Therapeutics Inc was Downgraded by Stifel on Nov 29, 2016 to Hold, Lowers Price Target to $ 3.25 from a previous price target of $16 .Nivalis Therapeutics Inc was Downgraded by Raymond James to Mkt Perform on Nov 29, 2016. Nivalis Therapeutics Inc was Downgraded by Robert W. Baird on Nov 29, 2016 to Neutral, Lowers Price Target to $ 3 from a previous price target of $29 .
Company has reported several Insider transactions to the SEC, on Jan 5, 2017, David Malcom Rodman (Exec Vice President and CMO) sold 6,687 shares at 2.27 per share price.On Dec 5, 2016, R Michael Carruthers (CFO) purchased 24,000 shares at 2.09 per share price.On Jun 17, 2016, Jon Congleton (CEO) purchased 5,000 shares at 3.87 per share price.
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 4 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.
Nivalis Therapeutics, Inc. (NASDAQ:NVLS): The mean estimate for the short term price target for Nivalis Therapeutics, Inc. (NASDAQ:NVLS) stands at $4.63 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $6 while the lower price target estimate is at $3.
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) rose 5.49% or 0.13 points on Tuesday and made its way into the gainers of the day. After trading began at $2.42 the stock was seen hitting $2.6 as a peak level and $2.38 as the lowest level. The stock ended up at $2.5. The daily volume was measured at 1,023,720 shares. The 52-week high of the share price is $9.35 and the 52-week low is $2. The company has a market cap of $39 million.
Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado.